Axsome Therapeutics at Jefferies: Strategic Growth and Pipeline Expansion

Investing.com

Published Jun 05, 2025 04:10PM ET

Axsome Therapeutics at Jefferies: Strategic Growth and Pipeline Expansion

On Thursday, 05 June 2025, Axsome Therapeutics (NASDAQ:AXSM) took center stage at the Jefferies Global Healthcare Conference 2025. The company discussed its strategic initiatives, highlighting both opportunities and challenges. Key topics included their commercial programs, pipeline progress, and future growth potential, with a focus on disciplined capital deployment and achieving cash flow positivity.

Key Takeaways

  • Axsome expects to achieve cash flow positivity with current resources and trajectory.
  • The launch of Simbravo for migraines is imminent, targeting headache centers.
  • Avelity's annualized run rate reached $400 million by the end of Q1.
  • The company is expanding its sales force for Avelity, targeting primary care.
  • Upcoming filings include AXS-5 for Alzheimer's agitation and AXS-14 for fibromyalgia.

Financial Results

Avelity:

  • Annualized run rate of $400 million by Q1 end.
  • Gross to net was 55% for Q1, expected to remain stable.
  • Frontline use at 15% of scripts; second-line use at 35%.

Operational Updates

Commercial Programs:

  • Sunosi: 75 reps, steady number.
  • Avelity: Expanded to 300 reps from 260 in Q1, targeting primary care.
  • Simbravo: Launching with 100 reps, focusing on 150 headache centers in the US.

Pipeline Progress:

  • AXS-5 (Alzheimer's agitation): SNDA filing on track for Q3.
  • AXS-12 (Narcolepsy): NDA submission underway.
  • AXS-14 (Fibromyalgia): NDA filed in Q1, awaiting FDA decision.
  • Sunosi (ADHD): Positive Phase III trial results; pediatric trial planned.

Future Outlook

Profitability:

  • Axsome aims to achieve cash flow positivity with existing resources.

Growth Drivers:

  • Avelity's expansion into primary care, with 20-25% of scripts from this sector.
  • Potential national DTC campaign for Avelity, currently tested regionally.
  • Enhanced coverage and reduced utilization management.

Q&A Highlights

Avelity in Alzheimer's Agitation:

  • Differentiated from atypical antipsychotics; an oral NMDA receptor antagonist.
  • Data shows significant separation in two to three weeks.

Simbravo Launch Strategy:

  • Targeting headache centers and specialists.
  • Initial prescribers write about two-thirds of branded scripts for acute migraines.

AXS-12 (Reboxetine) for Narcolepsy:

  • Focus on cataplexy with daytime dosing, addressing high unmet needs.

AXS-14 (Escoboxetine) for Fibromyalgia:

  • Data shows impact on fatigue, distinct from current treatments.
Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Sunosi for ADHD:

  • Pediatric trial needed to complete NDA or sNDA package.

For a detailed understanding, readers are encouraged to refer to the full transcript below.

Full transcript - Jefferies Global Healthcare Conference 2025:

Andrew Tsai, Senior Biotech Analyst, Jefferies: started with the next session. I'm Andrew Tsai, senior biotech analyst at Jefferies. Thanks for tuning in. And it's my pleasure to have Mark Jacobsen, Chief Operating Officer next to me from Axsome. Welcome.

Mark Jacobsen, Chief Operating Officer, Axsome: Hey, thanks. Thanks for having us, Andrew.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Yeah, you got it. So maybe briefly, introduction about Axsome, what you're working on, what your strategy is, and then maybe talk about some of these near term catalysts you're looking forward to. You've got a lot of programs.

Mark Jacobsen, Chief Operating Officer, Axsome: Sure. Great. Well, thanks again, Andrew, for having us. It's nice to be here. And so Axsome, obviously, we are a CNS focused biopharma.

We have had a pretty eventful year. But just to set the stage, we now have three commercial programs, two of which we developed internally. And one of those which is about to launch imminently, that is some Bravo for migraine that was approved earlier this year. The other two products are Ovelity for major depressive disorder and Sunosi for excessive daytime sleepiness and OSA, so obstructive sleep apnea and narcolepsy. And growth phase for all of those, and we can get into specifics, but we're pleased with execution to date.

And behind those we have three NDA stage programs. That's AXS-five in Alzheimer's disease agitation. There is AXS-fourteen in fibromyalgia and AXS-twelve in narcolepsy. So we can talk about each of those and the status of those programs. And then behind that, a number of clinical stage programs across a variety of CNS indications.

So happy to be here and just field questions as would help. And balance of the year, I think the biggest activities are just continued commercial execution across the programs and attending to the NDA stage work. And obviously continuing to drive enrollment in ongoing studies and starting a few studies.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Great. And so as I think about your programs that could be approved over the next twelve months or so, I mean, there's a good chance for all of them. And so let's just say they were all approved, launches go as planned. I mean, your company that seems to focus on ROI as well and profitability, when do you think you can hit profitability?

Mark Jacobsen, Chief Operating Officer, Axsome: No, thanks. We have guided to that with the current resources on hand and the current trajectory for the products on market that we expect to reach cash flow positivity. And we have not yet guided to a specific year or quarter but achieving that milestone is insight and it's not even on the horizon at this point in time. So we feel very good about the operating plan and how we are deploying capital in a disciplined fashion. And one key component of that is, you're right, we have three potential launches on the horizon in addition to some Bravo, which we expect to launch this month.

But there's high synergy and internal leverage with the sales teams that we have in place and the commercial infrastructure that we've built. So we'd expect a number of those potential launches to be very efficient in terms of capital deployment.

Andrew Tsai, Senior Biotech Analyst, Jefferies: And speaking of sales reps, can you give us some color around how many sales reps you have now for the existing business with Sunosi and Avelity for major depression and how you expect the evolution of the number of sales reps to unfold over the next year?

Mark Jacobsen, Chief Operating Officer, Axsome: Definitely. So Sunosi, it's about 75 reps, 70 four, 70 five reps. And that's been steady since we acquired their product a few years ago. And I think for the time being, we anticipate that number to stay steady. But looking to the future, that's a sleep field force.

And so there's high applicability to AXS-twelve, the product candidate for narcolepsy, should that be approved, and just adding another potential product to that team's bag. Avelity is currently at 300 reps. So we recently expanded that from approximately two sixty reps earlier this year in Q1. They're in the field now. They've been in the field since the end of the first quarter.

We're starting to see that impact in terms of a step in new to brand script, so NBRx. And we'd expect to see that pull through to TRx between now and at the end of the year and beyond. With internal leverage and applicability to future programs, of course, there's 80 agitation and other indication or products that may be relevant. But for the time being, we think 300 is right sized. But we're a data driven organization.

So if it makes sense, say, upon potential approvals or fertile grounds for additional investment, we won't rule that out. But right now, we think 300 is the right number for Ovelity and the psychiatry field force. Then if you look at Simbravo, we've shared that we'll be launching with an account management team, so the reps of 100 reps. And they're on board. They're finishing training right now.

And essentially, once they're done with training, they'll be in the field, and we'll have an update with respect to commercial availability.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Thank you. And so maybe a couple of questions on AVELITY, the ongoing launch performed very well. And the question is, why are you confident this could be a multi billion dollar opportunity in MDD alone, major depression alone? When I think about precedents like Rexulti, Vraylar cap light up, maybe they're expected to do in the 1,000,000,000 to $2,000,000,000 range. So what makes you confident you have a multi billion

Mark Jacobsen, Chief Operating Officer, Axsome: Oh, sure. Yeah, no, thanks. It's where the data are pointing to right now and where we are. So we're just north of two years into launch. And already the run rate annualized is $400,000,000 as of the end of the first quarter.

And it's based on just extrapolation of where things are today. And so where are we seeing utilization? Already, we're seeing frontline use at about 15% of the scripts, second line use at about 35% of those scripts, and then beyond. So that's a great place to be. It's a great place to be with we're at 63% of covered lives in the Commercials channel, about 78% total, so essentially 100% in the Government channel.

So that's a great place to be with our expected continued evolution of coverage. So that's both additional lives covered in the commercial channel and then improvements in the current type of coverage towards reductions in utilization management. So you'd expect that to continue. And of course, with respect to the other products that you mentioned, AVELITY is approved for MDD, so non adjunctive use. And when you think about that, again, already from launch, we're seeing monotherapy use in more than half of patients already.

And so that's a great place to be. It's really the confluence of those things and just the rate of scripts and NBRx puts us to those estimates.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Right. And then you mentioned extrapolation earlier, which you did settle with the first and only filer a month ago or not a month ago, but earlier this year for 2,038. So you've got a long tail. Okay, so that works.

Mark Jacobsen, Chief Operating Officer, Axsome: Exactly.

Andrew Tsai, Senior Biotech Analyst, Jefferies: And so as I think about 2025, the drivers behind sales, you've got new sales reps going on. You are, I believe, launching a national DTC campaign second half. What other drivers do you see?

Mark Jacobsen, Chief Operating Officer, Axsome: Sure. So the expansion, that's important because one thing we're doing, with that, you're increasing reach and frequency of HCPs that you're engaging with. And the increased reach here with what we're starting on now or increasing our efforts around is going into primary care. And scripts, it's about 2025% of scripts are coming from primary care right now. So there's a lot of work to be done there.

So that's a potential growth driver. You mentioned DTC. We do have a national DTC campaign that's in the works and could be rolled out as early as second half of this year. And what we're doing right now there, just to share is that there are some regional markets that that ad is being tested in right now. And we'll take learnings from that to inform potential national rollout.

So we can do that in our, again, just disciplined high ROI approach for something like a national DTC effort. And of course, that's one of the classic levers for potential growth driver. And then the other, we touched on this already, but it's a key consideration, is just evolution in coverage and for potential appropriate patients that if an HCP wants to write the script that it can be filled relatively easily. So that opens potential volume drivers as well. So those are the three, I think, primary categories.

And that's elbow grease associated with each of those and that's a key focus of the team.

Andrew Tsai, Senior Biotech Analyst, Jefferies: And then maybe one last question about this launch gross to net, I think was 55% for first quarter. Is it fair to assume it will continue to improve quarter over quarter for the rest of this year?

Mark Jacobsen, Chief Operating Officer, Axsome: You do have that backdrop where gross to nets in general trend down over the course of the year from a seasonality perspective. We said mid-50s and that we expect actually that to be relatively steady from Q1, Q2 and beyond for the year. And part of the reason for that is just that even though you have that backdrop where gross to net can improve over the year, because of the nature of coverage evolving and when you have changes in coverage, they're chunky, right? And that depends on how many plans maybe are implementing changes and the types of coverage and rebates that may be being accessed that we think would keep gross to net relatively steady for the time I see

Andrew Tsai, Senior Biotech Analyst, Jefferies: stable, okay. And then as this launch is going on, you're filing for the same compound SNDA in Q3. So it could be approved if you have priority review maybe mid-twenty twenty six. And so this is for Alzheimer's agitation. And when I think about the other Alzheimer's agitation drug approved, Axalty, the question would be why do you think the sales of that compound had been slow?

And maybe you think it's okay, but why would it be different for Avelity?

Mark Jacobsen, Chief Operating Officer, Axsome: Sure. Mean the team watches that. It's a little bit hard to speak to it specifically because obviously that's not our program. But if you look in the channel where four eighty agitation, so in the government channel Medicare Part D, those scripts are growing steadily. Maybe if you are referring to total scripts, believe the product is growing, but the key growth maybe is where they're shifting their attention to in Medicare Part D.

And so to us, it's informative. But you're right. I think there are a number of key distinctions. One is just mechanistically the product is much different. It's an oral NMDA receptor antagonist.

It's not an atypical antipsychotic. So we think that's a key element. And should the product be approved, we would anticipate the label to have other distinguishing characteristics or considerations. So take ADVANCE-one, for example, we saw separation in two weeks, which was stat sig in three weeks. And so we have maintenance of effect studies.

We have that's from an efficacy perspective, the safety and tolerability considerations or observations. The profile is distinct. So we think that we really like that. We like the package we have. And again, it's too early to comment on what a label could look like.

But based on the data we have in hand, it's a different molecule and profile. And we like that.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Yep. And Rexulti as an antipsychotic has a class black box warning for increased mortality. You don't think you'll get one, is that correct?

Mark Jacobsen, Chief Operating Officer, Axsome: Well, that warning is for atypical antipsychotics, And obviously, the product is not one. And so we would not anticipate an atypical antipsychotic warning. And that is the only product approved in the indication. So exactly, again, it's difficult to say, hey, the totality of labels look like this or that at this point in time. But yes, with respect to the atypical warnings or contraindications, would anticipate some distinction, mechanistic distinction.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Now, Avelity technically has SSRI plus NMDA. The question is, do you think you would, however, get a black box for suicidal ideation due to the antidepressant?

Mark Jacobsen, Chief Operating Officer, Axsome: Sure. And so would we given we plan to file as an sNDA, an efficacy supplement, that means it would be under the brand name of Avelity. And so the label does have that warning as an antidepressant for suicidal ideation. And so you'd expect that to be present with respect to use as an antidepressant. Beyond that, it's

Andrew Tsai, Senior Biotech Analyst, Jefferies: SPEAKER Right, right, And so in terms of the marketing strategy, is there something you plan to do differently that Rexulti is doing right now?

Mark Jacobsen, Chief Operating Officer, Axsome: I don't have specifics for you on, say, tactics, commercial tactics. I think we talked about a key element or a key differentiator, which is just the mechanistic or differentiation from the molecule. And also, touched on some of the differences in the clinical data we have, both from an efficacy perspective and safety and tolerability perspective. So those would ultimately flow into tactics. Yeah, we'll have more to say, but we're the team, the commercial team, medical affairs team, all that prep work is underway in anticipation of potential next steps for the program after a submission.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Okay. And then shifting gears, so that's on track for Q3?

Mark Jacobsen, Chief Operating Officer, Axsome: Yep, on track.

Andrew Tsai, Senior Biotech Analyst, Jefferies: And so shifting gears to Simbrava, which you mentioned earlier you're launching imminently. So we'll wait for that news. So what can we expect on gross to net for this product for acute migraine? When I think about oral CGRPs, may be pretty heavily discounted and there may be heavy use of free drug. Would it be different for Cimbravo here?

Mark Jacobsen, Chief Operating Officer, Axsome: Yeah, think we'd expect some differences, but you are right. Migraine as a category is managed much differently or payers manage it much differently from other categories in terms of you'd expect just or the way it's managed is right a PA to label, so confirmation of diagnosis, generally at least one generic triptan step and things like that. And so free goods are a component of launches here. Sampling, that's a component, and we'd expect to have those. However, the way we'll be launching is a targeted effort, we'll be focused on headache centers and headache specialists.

And so there are about 150 headache centers in The US. The 100 reps that we talked about, that will be the area of focus. And of course, those centers and our initial prescriber target base, they write about twothree of the branded scripts for acute migraine treatments. And many of those offices have the back office infrastructure and team to process PAs and support PA submissions. They're familiar with sampling.

And many of the patients have already many individuals who are being seen by a headache specialist already have already tried multiple acute migraine treatments. So that's where the initial focus will be, and then we'll go from there.

Andrew Tsai, Senior Biotech Analyst, Jefferies: The positioning wise, would this be used after a triptan, generic triptan, and then after a generic CGRP? How are you positioning the drug?

Mark Jacobsen, Chief Operating Officer, Axsome: Sure. So the clinical data that we generated for foursome Bravo, it's across a variety of migraine severities, which is great. And so that gives clinicians a variety of data points or data sets to make prescribing decisions. And if you speak to KOLs, they indicate they're interested in potentially using the product in a number of patient profiles. And if you step back, the reason for that is if you survey patients, there is still an overwhelming need in the market.

So there are a lot of treatment options. But patients are highly dissatisfied from an efficacy perspective. And so we're excited for the launch and the potential of the product. And I think it's going to ultimately say towards steady state where the bulk of it of potential prescribing, I think we'll see that's ultimately going to depend management and where we net out from a coverage perspective. But our goal, of course, is to secure coverage early on and through steady state that would allow as many appropriate patients that a clinician or HCP wants to write for that they're able to get the product that can.

Andrew Tsai, Senior Biotech Analyst, Jefferies: And then one last question before we shift gears is shape of the curve with the launch in terms of the sales trajectory. Is it slow and steady or some kind of rapid adoption?

Mark Jacobsen, Chief Operating Officer, Axsome: Sure. Scripts will be available and folks can watch. And so we haven't guided to that but we'll course we'll be watching that internally and others can as well. And I think once we get off the launch pad, we'll be able to comment on that with some type of informed commentary. Sure.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Then shifting gears to riboxetine. I believe you're filing this NDA after the Alzheimer's agitation, SNDA, shortly thereafter later this year.

Mark Jacobsen, Chief Operating Officer, Axsome: We said, yes, second half.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Second half, okay. Ultimately, can you also help us frame into context in the narcolepsy space where this would be positioned? When I think about narcolepsy, there's antidepressants, stimulants, oxybates, weight kicks. So where would this fit in?

Mark Jacobsen, Chief Operating Officer, Axsome: Yeah, so from a class or mechanistic perspective, it's an norepinephrine reuptake inhibitor. And so it's daytime dosing. We wouldn't expect scheduling, the initial focus, we're planning for this to be for cataplexy in narcolepsy. And of course we looked at other items across different studies in terms of impact of sleep or sleepiness and cognition. So we like the other endpoints that we analyzed and the data that we saw.

But yeah, so it's an orphan indication. It's not ultra orphan. And there is a high need and that can be with patients who may not tolerate say, the bulk of currently available products or, say, just under penetration with respect to treatment options. So there are we like the totality of the data and the overall product profile. And we're definitely looking forward to that submission.

And the work underway now is just the back office work of compiling the submission. One:

Andrew Tsai, Senior Biotech Analyst, Jefferies: Okay. And you have cataplexy data, so reducing attacks in NT1 narcolepsy. You mentioned you have data maybe on sleepiness. Have you shared that data? When can we expect to?

Mark Jacobsen, Chief Operating Officer, Axsome: We shared some of that data. So for example, CONCERT, the phase two trial, we shared some data there. And we've been presenting different data sets since the concert study. And of course, the clinical work is done now. I don't think it should surprise you if you see additional presentations coming up.

And there are a number of conferences coming up, even ones in a few weeks. And so, yeah, I think we'll continue to present the data and just keep cracking away at the NDA submission and then go from there.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Okay, okay. And then one more product that could be approved in next year is S Reboxetine, the right isomer of Reboxetine, but this time that's for fibromyalgia pain. I believe you filed around first quarter, maybe we're waiting for that acceptance any day now. So hence it could be approved in Q2 of next year maybe or Q1.

Mark Jacobsen, Chief Operating Officer, Axsome: Yes, that's possible. Don't have so right, next step is hearing for a potential acceptance decision of the NDA submission from FDA. And then should there be an acceptance, then would receive a potential PDUFA date that would allow us to comment. Yeah, you can do the math. We haven't shared the specifics yet, but I think your timing is I'm sure you've got the parameters correct.

And so, yeah, then share the next potential update for the program. And then if that's moving forward, launch work and pre commercial work, those gears have started turning as well.

Andrew Tsai, Senior Biotech Analyst, Jefferies: And if it is approved, why wouldn't someone want to use this product over existing drugs like Cymbalta or Lyrica?

Mark Jacobsen, Chief Operating Officer, Axsome: Sure. The clinical data, compelling with respect to pain and fibromyalgia. But if you go, say, to FDA's Voice of the Patient report on fibromyalgia, a key burden and symptom for individuals with fibromyalgia is the fatigue. And the product candidate, AXS-fourteen, that did show an effect and impact on fatigue. So that's important and that's distinct from what's currently available as one example.

And we like the overall profile and the data that were generated, but we'll see. Ultimately, and if potential approval would ultimately depend on the label of that. But that's a key consideration is this fatigue.

Andrew Tsai, Senior Biotech Analyst, Jefferies: You mentioned you don't think Reboxetine will be scheduled. Will Escoboxetine be scheduled?

Mark Jacobsen, Chief Operating Officer, Axsome: Yeah, we don't have an expectation of that either. Of course, mechanistically they are the same as you pointed out. Reboxetine is the racemic. S. Reboxetine is one of the stereo isomers.

And so there's different selectivity associated with that. But in terms of the AE profiles or things that might lead to scheduling, we don't have an expectation around that.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Okay, got it. And then another question is, you got this compound from Pfizer four years ago. So what exactly took you so long to file?

Mark Jacobsen, Chief Operating Officer, Axsome: Sure. Yeah, part of it is just us running air traffic control on all the programs. We have a lot going on, which is great. And it was us choreographing our work. But with respect to 14 in particular, we are recapitulating the manufacturing process.

So you're right, Pfizer was the initial company that they ran the clinical trials and did the manufacturing. That was discontinued. And so we had to go through the process for, as I mentioned, recapitulating the process and then putting up new stability batches, registration batches, and then waiting for the stability data, etcetera. And that work was underway and that was rate limiting for

Unidentified speaker: the

Andrew Tsai, Senior Biotech Analyst, Jefferies: Understood. In the last couple of minutes, maybe about your pipeline candidates, you have a whole bunch of phase three studies too as But maybe for the sake of this conversation, Sunosi for ADHD, I would just love to know what makes you excited about this profile in this indication area, why it ultimately could be differentiated.

Mark Jacobsen, Chief Operating Officer, Axsome: Yeah. I mean, there's ADHD, there's a high need. So stimulants, there's a non stimulant available. The prevalence of the indication and then the impact to one's life is substantial. And then you have a variety of, depending on the individual and what they may have been prescribed, there are a variety of, say, tolerability questions or scheduling questions.

And then on the other end of that spectrum, efficacy questions. So there is a need. Sunosi, for salriamfetol for ADHD, the feedback, we were interested in that program initially because of feedback from KOLs and the mechanistic relevance, but also the feedback on, say, global patient, global changes for patients that have been prescribed the product that it's how they do. And so that's what led to wanting to actually explore sauramfetol in a number of additional indications. And ADHD, of course, there's a large need.

It's a large market. And so yeah, we had the FOCUS Phase III trial. That was in adults that read out earlier this year. Positive trial, which is great. And the next part of that program is a pediatric adolescent trial, which we need per FDA feedback to round out a potential NDA or sNDA package.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Okay. And then the last question in this program is in what dose you're picking multiple doses for the pediatric or just one dose? Doctor.

Mark Jacobsen, Chief Operating Officer, Axsome: Oh, no, that's a great question. We haven't shared that yet. I think you could probably when we would comment on that is say trial initiation. But that is a consideration. For the pediatric trials, typically that happens behind the scenes for programs as post marketing commitments or requirements.

And here, because of the indication, FDA requires it in advance. So that is one of the considerations that goes into the study design.

Andrew Tsai, Senior Biotech Analyst, Jefferies: Okay. Well, that's all the time we have. Thank you so much for giving us an update about your programs and lots of things going on.

Mark Jacobsen, Chief Operating Officer, Axsome: Thanks for having us, Andrew. Really appreciate it. Thanks.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes